+1 347 708 0418
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs size is estimated to be xx million in 2021 from USD 1290.9 million in 2020, with a change of XX% between 2020 and 2021. The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size is expected to grow at a CAGR of 10.2% for the next five years.
Market segmentation
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
Market segment by Application can be divided into
Hospitals
Clinics
Others
The key market players for global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market are listed below:
Astellas Pharmaceuticals
Actavis
Pfizer
GlaxoSmithKline
Salix Pharmaceuticals Ltd
AstraZenenca
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with price, sales, revenue and global market share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs from 2019 to 2021.
Chapter 3, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Eluxadoline
1.2.3 Alosetron
1.2.4 Rifaximin
1.2.5 Loperamide
1.2.6 Diphenoxylate + Atropine
1.2.7 Dicyclomine and Hyoscyamine
1.3 Market Analysis by Application
1.3.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size & Forecast
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Value (2016-2026))
1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume (2016-2026)
1.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2016-2026) & (USD/MT)
1.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity Analysis
1.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Production Capacity (2016-2026)
1.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
1.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
1.6.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Astellas Pharmaceuticals
2.1.1 Astellas Pharmaceuticals Details
2.1.2 Astellas Pharmaceuticals Major Business
2.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Actavis
2.2.1 Actavis Details
2.2.2 Actavis Major Business
2.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.2.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.3.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Salix Pharmaceuticals Ltd
2.5.1 Salix Pharmaceuticals Ltd Details
2.5.2 Salix Pharmaceuticals Ltd Major Business
2.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.5.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 AstraZenenca
2.6.1 AstraZenenca Details
2.6.2 AstraZenenca Major Business
2.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
2.6.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturer
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Manufacturer (2019-2021e)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2019-2021e)
3.3 Key Manufacturer Market Position in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share
3.4.2 Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share
3.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Company
3.6 Manufacturer by Geography: Head Office and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Region (2016-2026)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2026)
4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026)
4.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026)
4.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026)
4.5 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026)
4.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026)
5 Market Segment by Type
5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Type (2016-2026)
5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2016-2026)
5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2016-2026)
6 Market Segment by Application
6.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Application (2016-2026)
6.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2016-2026)
6.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2016-2026)
7 North America by Country, by Type, and by Application
7.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2026)
7.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2026)
7.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
7.3.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2016-2026)
7.3.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2026)
7.3.3 United States Market Size and Forecast (2016-2026)
7.3.4 Canada Market Size and Forecast (2016-2026)
7.3.5 Mexico Market Size and Forecast (2016-2026)
8 Europe by Country, by Type, and by Application
8.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2026)
8.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2026)
8.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
8.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2016-2026)
8.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2026)
8.3.3 Germany Market Size and Forecast (2016-2026)
8.3.4 France Market Size and Forecast (2016-2026)
8.3.5 United Kingdom Market Size and Forecast (2016-2026)
8.3.6 Russia Market Size and Forecast (2016-2026)
8.3.7 Italy Market Size and Forecast (2016-2026)
9 Asia-Pacific by Country, by Type, and by Application
9.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2026)
9.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2026)
9.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region
9.3.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Region (2016-2026)
9.3.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2026)
9.3.3 China Market Size and Forecast (2016-2026)
9.3.4 Japan Market Size and Forecast (2016-2026)
9.3.5 Korea Market Size and Forecast (2016-2026)
9.3.6 India Market Size and Forecast (2016-2026)
9.3.7 Southeast Asia Market Size and Forecast (2016-2026)
9.3.8 Australia Market Size and Forecast (2016-2026)
10 South America by Country, by Type, and by Application
10.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2026)
10.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2026)
10.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
10.3.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2016-2026)
10.3.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2026)
10.3.3 Brazil Market Size and Forecast (2016-2026)
10.3.4 Argentina Market Size and Forecast (2016-2026)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2026)
11.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2026)
11.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Country
11.3.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales in Volume by Country (2016-2026)
11.3.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2026)
11.3.3 Turkey Market Size and Forecast (2016-2026)
11.3.4 Egypt Market Size and Forecast (2016-2026)
11.3.5 Saudi Arabia Market Size and Forecast (2016-2026)
11.3.6 South Africa Market Size and Forecast (2016-2026)
12 Sales Channel, Distributors, Traders and Dealers
12.1 Sales Channel
12.1.1 Direct Marketing
12.1.2 Indirect Marketing
12.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Distributors
12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type, (USD Million), 2021-2026
Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application, (USD Million), 2021-2026
Table 3. Astellas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Astellas Pharmaceuticals Major Business
Table 5. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 6. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 7. Actavis Basic Information, Manufacturing Base and Competitors
Table 8. Actavis Major Business
Table 9. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 10. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 11. Pfizer Basic Information, Manufacturing Base and Competitors
Table 12. Pfizer Major Business
Table 13. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 14. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 15. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 16. GlaxoSmithKline Major Business
Table 17. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 18. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 19. Salix Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 20. Salix Pharmaceuticals Ltd Major Business
Table 21. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 22. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 23. AstraZenenca Basic Information, Manufacturing Base and Competitors
Table 24. AstraZenenca Major Business
Table 25. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 26. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Price (USD/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2021e)
Table 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturer (2019-2021e) & (K MT)
Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2019-2021e) & (USD Million)
Table 29. Market Position of Manufacturers in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2020
Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Company, (K MT): 2020 VS 2021
Table 31. Head Office and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Site of Key Manufacturer
Table 32. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs New Entrant and Capacity Expansion Plans
Table 33. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Mergers & Acquisitions in the Past Five Years
Table 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2021e) & (K MT)
Table 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2026) & (K MT)
Table 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2021-2026) & (USD Million)
Table 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021e) & (K MT)
Table 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K MT)
Table 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2016-2021e) & (USD Million)
Table 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2021-2026) & (USD Million)
Table 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2016-2021e) & (USD/MT)
Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2021-2026) & (USD/MT)
Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2021e) & (K MT)
Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K MT)
Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2016-2021e) & (USD Million)
Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application (2021-2026) & (USD Million)
Table 48. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2016-2021e) & (USD/MT)
Table 49. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2021-2026) & (USD/MT)
Table 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021e) & (K MT)
Table 51. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K MT)
Table 52. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 53. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2026) & (USD Million)
Table 54. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021e) & (K MT)
Table 55. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K MT)
Table 56. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2021e) & (K MT)
Table 57. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K MT)
Table 58. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021e) & (K MT)
Table 59. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K MT)
Table 60. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 61. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2026) & (USD Million)
Table 62. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021e) & (K MT)
Table 63. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K MT)
Table 64. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2021e) & (K MT)
Table 65. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K MT)
Table 66. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2016-2021e) & (K MT)
Table 67. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Region (2021-2026) & (K MT)
Table 68. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2016-2021e) & (USD Million)
Table 69. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Region (2021-2026) & (USD Million)
Table 70. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021e) & (K MT)
Table 71. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K MT)
Table 72. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2021e) & (K MT)
Table 73. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K MT)
Table 74. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021e) & (K MT)
Table 75. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K MT)
Table 76. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 77. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2026) & (USD Million)
Table 78. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021e) & (K MT)
Table 79. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K MT)
Table 80. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2021e) & (K MT)
Table 81. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K MT)
Table 82. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2016-2021e) & (K MT)
Table 83. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Country (2021-2026) & (K MT)
Table 84. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2016-2021e) & (USD Million)
Table 85. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Country (2021-2026) & (USD Million)
Table 86. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2016-2021e) & (K MT)
Table 87. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2021-2026) & (K MT)
Table 88. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2016-2021e) & (K MT)
Table 89. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2021-2026) & (K MT)
Table 90. Direct Channel Pros & Cons
Table 91. Indirect Channel Pros & Cons
Table 92. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Distributors
Table 93. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Typical Customers
List of Figures
Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Picture
Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2020
Figure 3. Eluxadoline
Figure 4. Alosetron
Figure 5. Rifaximin
Figure 6. Loperamide
Figure 7. Diphenoxylate + Atropine
Figure 8. Dicyclomine and Hyoscyamine
Figure 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2020
Figure 10. Hospitals
Figure 11. Clinics
Figure 12. Others
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size, (USD Million) & (K MT): 2020 VS 2021 VS 2026
Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Forecast (2016-2026) & (USD Million)
Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (2016-2026) & (K MT)
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2016-2026) & (USD/MT)
Figure 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity (2016-2026) & (K MT)
Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Production Capacity by Geographic Region: 2020 VS 2021
Figure 19. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers
Figure 20. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints
Figure 21. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturer in 2020
Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturer in 2020
Figure 24. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 25. Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2020
Figure 26. Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2020
Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2026)
Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2016-2026)
Figure 29. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026) & (USD Million)
Figure 30. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026) & (USD Million)
Figure 31. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026) & (USD Million)
Figure 32. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026) & (USD Million)
Figure 33. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (2016-2026) & (USD Million)
Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2026)
Figure 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Type (2016-2026)
Figure 36. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2016-2026) & (USD/MT)
Figure 37. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2026)
Figure 38. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2016-2026)
Figure 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2016-2026) & (USD/MT)
Figure 40. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2026)
Figure 41. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2026)
Figure 42. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2026)
Figure 43. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2026)
Figure 44. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2026)
Figure 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2026)
Figure 49. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2026)
Figure 50. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2026)
Figure 51. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. United Kingdom Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2026)
Figure 57. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2026)
Figure 58. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2016-2026)
Figure 59. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2016-2026)
Figure 60. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2026)
Figure 67. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2026)
Figure 68. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2026)
Figure 69. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2016-2026)
Figure 73. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2016-2026)
Figure 74. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Country (2016-2026)
Figure 75. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Buy
